Tumour suppressor gene (TSG) methylation has been proposed as a diagnostic marker for urothelial cancer (UC). Here, we compare the frequency of urinary TSG methylation in young and elderly patients, with and without UC. Urine samples were obtained prospectively from 35 UC patients, 35 benign controls over the age of 70 years and 34 healthy volunteers under the age of 40 years. Methylation analysis was performed for eight gene promoters using quantitative methylation-specific PCR. Methylation was detected in urine DNA from all three patient groups. The highest frequencies were seen in UC patients. Significantly less methylation was present in control samples than UC cases for RASSF1a and APC (Po0.034). The 'methylation index' and level of methylation was highest in the UC group and lowest in the young control group. A marker panel of RASSF1a, E-cad and APC generated a sensitivity of 69%, a specificity of 60% and a diagnostic accuracy of 86%. TSG methylation is detectable in urine DNA from patients with and without bladder cancer. The frequency and extent of methylation appears to increase with age and malignancy. The lack of tumour specificity suggests that further investigation is required before this test is introduced into clinical practice.
Tumour suppressor gene (TSG) methylation has been proposed as a diagnostic marker for urothelial cancer (UC). Here, we compare the frequency of urinary TSG methylation in young and elderly patients, with and without UC. Urine samples were obtained prospectively from 35 UC patients, 35 benign controls over the age of 70 years and 34 healthy volunteers under the age of 40 years. Methylation analysis was performed for eight gene promoters using quantitative methylation-specific PCR. Methylation was detected in urine DNA from all three patient groups. The highest frequencies were seen in UC patients. Significantly less methylation was present in control samples than UC cases for RASSF1a and APC (Po0.034). The 'methylation index' and level of methylation was highest in the UC group and lowest in the young control group. A marker panel of RASSF1a, E-cad and APC generated a sensitivity of 69%, a specificity of 60% and a diagnostic accuracy of 86%. TSG methylation is detectable in urine DNA from patients with and without bladder cancer. The frequency and extent of methylation appears to increase with age and malignancy. The lack of tumour specificity suggests that further investigation is required before this test is introduced into clinical practice. Oncogene (2006 Oncogene ( ) 25, 1984 Oncogene ( -1988 Oncogene ( . doi:10.1038 published online 14 November 2005 Keywords: epigenetic; DNA methylation; bladder cancer; urinalysis Bladder cancer is the fourth commonest malignancy amongst men in the western world and accounted for over 53 000 new cases in the United States in 2001 (Greenlee et al., 2001) . The commonest pathological variety is urothelial carcinoma (UC), which occurs as either a superficial or invasive phenotype. Tumours are usually diagnosed following an episode of haematuria, using flexible endoscopy (cystoscopy) to visualize the bladder. The majority of UC (70%) are of the superficial phenotype and most patients (>50%) with these tumours develop more than one UC in their lifetime. These patients undergo lifelong cystoscopic surveillance to detect subsequent tumour recurrence. New noninvasive methods for the diagnosis and surveillance of UC are required to replace cystoscopy. This procedure is expensive, uncomfortable and has a small morbidity. Exfoliated tumour cells are found in the urine of UC patients and cytological analysis has been used for many years to detect these tumours (Brown, 2001 ). However, cytology has a low sensitivity for UC and is userdependent, making it a poor screening test. Analysis of the DNA extracted from exfoliated cells can be used for noninvasive UC detection (Steiner et al., 1997) . Most molecular biomarkers analysed to date, lack sufficient specificity or sensitivity for their widespread use, and require extensive genetic analysis preventing their routine clinical use (Molinie et al., 2001) . A promising biomarker recently investigated is aberrant DNA promoter hypermethylation (Dulaimi et al., 2004) . This epigenetic marker has potential benefits over previously analysed genetic investigations, as it occurs widely throughout cancerous cells (thus only several loci need analysis) and always affects the same genomic loci (promoter regions) allowing minimal analysis.
DNA methylation is the addition of a methyl group to the cytosine ring of the CpG dinucleotide, forming methyl-cytosine and is catalysed by DNA methyltransferases. It occurs ubiquitously throughout the genome and when found in a promoter is associated with silencing of the affiliated gene. In carcinogenesis, the control of methylation is lost and results in both global hypomethylation and regional hypermethylation. Silencing of tumour suppressor genes (TSG) associated with aberrant hypermethylation has been shown to be a molecular pathway for human cancer development (Herman and Baylin, 2003) . As promoter hypermethylation occurs frequently in UC (Catto et al., 2005) , several authors have investigated its detection in exfoliated urinary cells as a novel diagnostic test (Maruyama et al., 2001; Chan et al., 2002; Dulaimi et al., 2004; Friedrich et al., 2004) . Recently, Dulaimi et al. (2004) found that analysis of hypermethylation using a panel of TSG's yielded superior results to cytology in the detection of bladder cancer. The authors concluded that methylation analysis had a role as a noninvasive urine test for the early detection of bladder cancer. However, there is increasing evidence that aberrant methylation is not cancer specific and can be found in a normal ageing cell population (Issa, 2004) . Toyota et al. (1999) investigated a series of colon cancers and hypothesized that methylation occurred in both age and tumour-specific patterns. While none of the urinalysis studies to date have had large control populations, two reports have shown aberrant methylation in normal urothelial tissues. Bornman et al. (2001) found E-Cadherin methylation in histologically normal bladders (3/9 studied) from elderly patients and Habuchi et al. (2001) found weak methylation of the DBCCR1 gene in normal urothelium. This was also found to be associated with ageing.
Thus, while there are technical reasons to optimise the detection of aberrant hypermethylation for bladder cancer diagnosis, this marker may not be cancer specific. We analysed a prospectively collected series of urine samples from cancer and control patients, using a quantitative fluorometric real-time methylation-specific PCR assay (QMSP) for aberrant methylation of eight gene promoter regions (RASSF1a, E-Cadherin, APC, p16, p14, GSTP, DAPK and RARb). To investigate the role of ageing, the control patients were stratified into young (under 40 years of age) and elderly (over 70 years of age) age groups. We prospectively collected urine samples from three groups of patients treated at the Royal Hallamshire Hospital, Sheffield, United Kingdom. Group 1 comprised 35 patients with a new diagnosis of UC. This group had a median age of 75 years (range 54-92) and comprised 30 (86%) males. There were 28 current or ex-smokers, four nonsmokers and smoking status was unknown in three. The tumours were representative of UC with 18 pTa, 12 pT1 and 5 pT2-4 tumours. Urine was collected prior to their first trans-urethral tumour resection. Group 2 was composed of 35 elderly patients (age >70 years) with no current or previous diagnosis of bladder or other cancer. These patients were identified through local clinics, and presented with either haematuria or lower urinary tract symptoms suggestive of UC. All had flexible cytoscopy and upper urinary tract imaging to exclude the presence of urinary cancers. Urine was collected prior to cystoscopy. The median age of this group was 76, and there were 32 males. 24 were current or ex-smokers, six nonsmokers and smoking status was unknown in five. Group 3 comprised 34 patients without a cancer diagnosis, all of whom were under 40 years of age. These patients were identified through the local genitourinary health clinic. None of the patients in this group had haematuria or symptoms suggestive of UC. The median age of this group was 29 and there were 27 males. In all, 16 were current or ex-smokers, 14 were nonsmokers and smoking status was unknown for four. No indication existed to perform cystoscopy in this group. From each patient, 100 ml of urine was collected as a freshly voided mid-stream specimen and immediately centrifuged for 30 min at 3500 r.p.m. The cellular pellet was twice washed in phosphate buffered solution (0.172 M) and recentrifuged, before freezing and storing at À801C until use.
Methylation was frequently detected in urinary DNA from all three patient groups, for the promoters of RASSF1a, APC and E-Cadherin ( Figure 1 and Table 1 ). For RASSF1a and APC the highest frequencies of methylation were seen in the UC patient group, when compared to the other two groups (w 2 ; P ¼ 0.1 for RASSF1a and P ¼ 0.018 for APC). When groups were individually compared, more methylation was present in group 1 compared to group 3 (RASSF1a and APC; w 2 P ¼ 0.034 and 0.08, respectively). E-Cadherin was most commonly methylated in group 2 (control patients >70, w 2 P ¼ 0.22), when compared to the other groups. While DAPK, GSTP and RARb were infrequently methylated in the three groups, no methylation of p14 and p16 was detected (Table 1) . From the methylation results we calculated a methylation index (MI) for each specimen.
The mean MI for group 1, 2 and 3 were 16.7, 14.6 and 10.2, respectively ( Figure 2 ). The mean gene:b-actin ratios were calculated for the three most frequently methylated genes. For RASSF1a and APC (Figure 3 ), the level of methylation was significantly higher in group 1 compared to groups 2 and 3 (t-test; APC Po0.0001, RASSF1a P ¼ 0.06). For E-Cadherin, the highest levels of methylation were present in group 2, when compared with groups 1 and 3 (t-test; P ¼ 0.126). Overall, the mean methylation level for group 1 was 29.16, for group 2 was 15.9 and for group 3 was 8.9 (t-test; P ¼ 0.086). For the three frequently methylated gene promoters (RASSF1a, APC and E-Cadherin), we calculated the sensitivity, specificity and diagnostic accuracy. The sensitivity for RASSF1a, APC and E-cad was 0.51, 0.4 and 0.31, respectively. The specificity was 0.63, 0.83 and 0.53, respectively. The individual diagnostic accuracy of RASSF1a, APC and E-cad was 0.61, 0.69 and 0.47, respectively. Using a methylation panel comprising RASSF1a, APC and E-cad, a sensitivity of 0.69, a specificity of 0.6 and a diagnostic accuracy of 0.86 resulted. Methylation frequency was not associated to smoking status in either group (w 2 ; P ¼ 0.8). Investigators have identified that aberrant DNA methylation is associated with the development of human cancer (Herman and Baylin, 2003) . This has prompted numerous groups to investigate the clinical implications of methylation and in particular its role in the noninvasive diagnosis of cancer (Laird, 2003) . However, our overall knowledge of the molecular mechanisms of DNA methylation in health and cancer remains poor. One uncertainty is the extent of aberrant DNA methylation in nonmalignant tissue and its increase in ageing. It has been suggested that there is a direct association between ageing and aberrant DNA methylation (Issa et al., 1994) , and that this would perhaps (partly) explain the direct association between ageing and the increased incidence of cancer. For example, Ahuja et al. (1998) demonstrated age-related methylation for four genes in normal colonic mucosa from a panel of eight genes known to be methylated in CRC. Toyota et al. (1999) identified two distinct patterns of CpG methylation in colorectal cancer Figure 1 (a-c) RASSF1a promoter methylation analysis using quantitative real-time methylation-specific PCR (QMSP). Examples of QMSP for the three patient groups are shown (a; UC patients, b; controls aged >70 years old and c; controls aged o40 years). Figures on Y-axis of graphs represent the Delta Rn measurement using the ABI prism 7000 sequence detection system. A standard phenochloroform extraction was used to obtain DNA from the washed and frozen cellular pellet obtained from centrifuged urine. For methylation analysis, approximately 1 mg of DNA was treated with sodium bisulphite for 16 h (Herman et al., 1996) , using the CpGenome kit (Chemicon, Hampshire, UK) according to the manufacturers's instructions. Eight gene promoter regions were investigated using QMSP and b-actin was used as the reference gene. Universally methylated DNA (Chemicon, Hampshire, United Kingdom) was used as a positive control. QMSP was performed with Accuprime Taq polymerase (Invitrogen, Paisley, UK) using the ABI prism 7000 sequence detection system. The primers and fluorescence labelled probes are described in detail elsewhere (Harnden et al., 2003) and were supplied by MWG Biotech (UK). A 10 ml PCR reaction volume was used, which comprised of 1 ml Accuprime buffer, 0.25 ml Accuprime Taq polymerase (Invitrogen, UK), 5 pM forward and reverse primers, 5 pM probe, 0.2 ml Rox reference dye and water. Sixty cycles of denaturation (951C for 45 s), annealing (specific primer temperature for 2 min) and extension (721C for 1 min) (Catto et al., 2005) were used. Samples without b-actin amplification were not analysed for promoter methylation.
(CRC) and termed these ageing (type A) and cancer (type C) specific. The frequency of these patterns in normal epithelium from benign and cancer colectomy specimens varied, supporting their work.
Aberrant promoter methylation is a common event in UC, which varies in frequency according to the gene and tumour factors. However, as with CRC, methylation does not appear to be cancer specific and reports have shown age-related methylation in UC (Habuchi et al., 2001) and in normal bladder mucosa (Bornman et al., 2001) . This has particular relevance to the development of methylation analysis as a noninvasive diagnostic test to detect bladder cancer. To date, several groups have successfully used this strategy to detect UC from urine samples. For example, Chan et al. (2002) investigated the methylation of seven genes (RARb, DAPK, ECadherin, p16, p15, GSTP and MGMT) in 22 voided urine samples from patients with UC and 17 controls. In the 22 paired urine samples, methylation of DAPK, RARb, E-cad and p16 could be detected in 45.5, 68.2, 59.1 and 13.6% of cases, respectively. The sensitivity of methylation analysis (90.9%) was higher than that of urine cytology for cancer detection. In the 17 normal control urine samples, no aberrant methylation was detected except for RARb in four cases (23.5%). Dulaimi et al. (2004) analysed urine DNA from 45 UC patients and 12 normal healthy individuals, for methylation of a TSG panel consisting of APC, RASSF1a and p14. Methylation was detected in 39 out of 45 patients (87% sensitivity; 100% specificity), including 16 cases with negative cytology. No methylation was observed in urine DNA from control group (12 patients). While both these reports appear to contrast with our data, it is important to stress that there are key methodological Table 1 Methylation frequencies and levels (gene:b-actin ratio) across the 3 groups for the 8 gene promoters studied Mean Methylation Index (95% CI) Figure 2 Mean methylation index for each of the three patient groups. The mean methylation index (number of loci methylated/ total number loci analysed 100 Â ) was highest for the UC group when compared to the other patient groups. However, the difference between each group failed to reach statistical significance (t-test, P>0.05). P<0.0001 Figure 3 Mean methylation levels for APC gene promoter in the three groups. Significantly higher levels of methylation were present in the UC group when compared to the two age stratified control groups (t-test, Po0.0001). To calculate the methylation level, the presence or absence, and relative quantity of methylation was measured for each sample at each promoter. The quantity was expressed as a ratio, based on the level of fluorescence released by the QMSP reaction, compared with that corresponding sample's b-actin level. This was expressed as QMSP:b-actin and multiplied by 100 (for simpler analysis), as previously used (Usadel et al., 2002; Catto et al., 2005) . differences with our work. Both Chan et al. (2002) and Dulaimi et al. (2004) used nonquantitative nonfluorometric methylation-specific PCR (MSP) to investigate promoter methylation. This method may fail to detect low concentrations of methylated alleles, unlike QMSP which can detect up to 1/1000 methylated alleles (own data not shown and Harnden et al., 2003) . Support for this explanation comes from work by Friedrich et al. (2004) , who analysed the methylation status of 12 apoptosis-associated genes including RASSF1a and DAPK in 127 UC samples and 37 samples of adjacent normal mucosa, using the quantitative fluorometric MethyLight technique. Urine DNA was analysed for 20 cancer free volunteers and 37 UC patients. Using a panel of DAPK, TERT and BCL2, an overall detection level of 78% for urine UC DNA was found. In the cancer free control group frequent methylation was found in the urine DNA for RASSF1a, EDNRB and TNFRSF25. Interestingly, the control groups were subdivided according to age. In a group under the age of 29 low levels of methylation of RASSF1a, EDNRB and TNFRSF25 was found. For the group over the age of 56, enhanced methylation levels (data not supplied in the report) for the same 3 genes were detected, but not as high as the levels in the cancer group samples. This is the only study, to our knowledge, assessing methylation in an age stratified control population and comparing it to methylation in a group of patients with malignancy. In support of these recent findings (Friedrich et al., 2004) , we have also found TSG methylation is often present in the exfoliated urinary cells from both cancer and control patients. Furthermore, the frequency of methylation at several loci increases with age and malignancy, supporting the description in other reports (Issa et al., 1994; Ahuja et al., 1998) . It is uncertain whether the high frequency detected in elderly patients with benign pathology reflects a pathological or physiological process and it is unclear why there should be methylation of known TSG in the urine from young patients without cancer. Both these factors suggest that methylation urinalysis (using these loci) may not demonstrate the desired specificity for routine clinical use. While our study was limited by the small panel of genes used for methylation analysis and the size of the various investigated groups, two conclusions may be drawn. Firstly, from our results and those of Friedrich et al. (2004) it appears that TSG methylation can be found in exfoliated urinary cells from patients without cancer and increases in frequency with ageing. Thus, while methylational urinalysis has a number of attractive features, each targeted locus should be thoroughly investigated in a large control population (of mixed aged volunteers) for tumour specificity, before clinical introduction. Secondly, quantified methylation analysis (e.g. QMSP or MethyLight) appears more sensitive to traditional MSP, and should be the method of choice for these analyses.
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